Nanite is a next-generation non-viral gene delivery company developing a new class of programmable polymer nanoparticles for a range of modalities and indications. The company’s AI-driven platform, SAYER, combines cutting-edge high-throughput experimental and computational methods to design fit-for-purpose delivery vehicles delivering a broad range of genetic cargoes with tissue specificity.
| Website | https://www.nanitebio.com |
| Employees | 17 (11 on RocketReach) |
| Address | 25 Dry Dock Ave, Boston, Massachusetts 02210, US |
| Industry | Biotechnology Research |
| Keywords | Gene Editing, Therapeutics, Gene Therapy, Biotechnology, Precision Medicine, Next Generation Therapeutics, Pharmaceutical Technology, Nanomedicine, Drug Delivery, Targeted Drug Delivery, Nanoparticle Technology, Drug Development, Novel Drug Delivery Systems, Polymer Chemistry, Ai Driven Platform, High Throughput Screening, Clinical Trials |
| Competitors | Sanofi, Amgen, Moderna Therapeutics, Alnylam Pharmaceuticals, Intellia Therapeutics, Inc., CRISPR Therapeutics, Editas Medicine, REGENXBIO Inc., Sangamo Therapeutics, Inc., Caribou Biosciences +28 more (view full list) |
Looking for a particular Nanite employee's phone or email?
Sean Kevlahan is the Chief Executive Officer and Co-Founder of Nanite.
11 people are employed at Nanite.
Nanite is based in Boston, Massachusetts.